Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05769777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05769777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 3, 2023
Completion date
June 11, 2031
Enrollment
999 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis atopic